权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Real-Time Optical Feedback for the Control of In Vivo Nanoparticle Concentration

用于控制体内纳米颗粒浓度的实时光学反馈

基本信息

批准号：
7803989
负责人：
Glenn P Goodrich
金额：
$ 11.37万
依托单位：
NANOSPECTRA BIOSCIENCES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-30 至 2012-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7803989
关键词：
Address Adverse effects Affect Algorithms Animals Area Biodistribution Biological Biological Availability Biomedical Engineering Blood Blood Circulation Blood specimen Bypass Clinical Clinical Research Conscious Devices Diagnosis Dose Drug Delivery Systems Drug Kinetics Environment Feedback Fingers Goals Gold Grant Hospitals Human Image Individual Industry Intervention Intravenous Kinetics Laboratories Light Link Location Louisiana Malignant Neoplasms Measurement Measures Medical Monitor Mus Nanotechnology Neighborhoods Optics Organ Patients Performance Physicians Physiologic pulse Physiological Procedures Process Reaction Relative (related person)Reproducibility Research Proposals Study Subject System Techniques Testing Therapeutic Therapeutic Agents Therapeutic Intervention Time Tissues Treatment Efficacy Tumor Burden Universities Validation Weight Work absorption animal facility base cancer cell cancer health disparity cancer therapy clinical efficacy clinically relevant cost design experience follow-up glucose sensor improved in vivo instrumentation nanoparticle nanoshell particle pre-clinical prototype public health relevance success theories tool

项目摘要

DESCRIPTION (provided by applicant): There is an immediate and urgent clinical need to enhance the monitoring of the delivery and accuracy of targeted drug delivery, the onset and spread of cancers, and the longitudinal monitoring of cancer treatments. Nanotechnology holds the promise to address this problem. A "smart" particle capable of selective targeting would augment the physician's tools needed for correct diagnosis and allow the treatment and follow-up procedures to be monitored in real-time. In an ideal clinical study, each subject would be injected with a precise number of nanoparticles related to the weight and tumor-burden of the subject in order to achieve a satisfactory therapeutic result. We propose that Nanospectra Biosciences, Inc. will join with the Biomedical Engineering Department at Louisiana Tech University (Ruston, LA) to test the feasibility of an inexpensive, clinically applicable optical tool to provide instantaneous quantitative information to support the delivery and circulation of therapeutically relevant nanoparticles. Independently, Tech will develop a clinical prototype, to be placed on a finger or other optically accessible location, in order to monitor the accuracy of the delivered dose and assess the effective circulation time immediately after intravenous delivery but prior to therapeutic intervention. The feasibility of the prototype to provide three clinical objectives will be assessed: (1) real- time feedback for practitioners to provide instantaneous initial dose verification, (2) real-time feedback providing therapeutic dose verification (np*min/mL), which is a pharmacokinetic analysis integrating the delivered dose and the circulation time, and (3) an alarm system which identifies a uncharacteristic shortened circulation time, which could help predict a physiological reaction to the nanoparticles, and which may require a medical intervention. This project's societal goals are to "accelerate work in nanotechnology, ...linking nanotechnology into cancer applications ... to dramatically reduce the adverse effects of cancer with multifunctional, targeted devices capable of bypassing biological barriers to deliver multiple therapeutic agents in high concentrations directly to cancer cells and tissues while sparing healthy tissue." This grant is also designed to deal with the problems of cancer health disparities, by developing easy-to-use cost-conscious instrumentation designed specifically to address the "impact of many factors, including physician experience, hospital environment, and the socio-demographics of each patient's neighborhood". PUBLIC HEALTH RELEVANCE: Nanoparticles hold significant promise for new and improved therapeutic and imaging applications and are being widely investigated. Preclinical and clinical use is affected by the "bio-availability" of these materials in vivo. This research proposal will develop a new device for real-time tracking of circulation kinetics for these new materials.

描述（由申请人提供）：目前迫切需要加强对靶向药物递送的递送和准确性、癌症的发作和扩散以及癌症治疗的纵向监测的监测。纳米技术有望解决这一问题。能够选择性靶向的“智能”粒子将增强医生正确诊断所需的工具，并允许实时监测治疗和随访程序。在理想的临床研究中，每个受试者将被注射与受试者的体重和肿瘤负荷相关的精确数量的纳米颗粒，以实现令人满意的治疗结果。我们建议Nanospectures Biosciences，Inc.将与路易斯安那理工大学（路易斯安那州拉斯顿）的生物医学工程系合作，测试一种廉价、临床适用的光学工具的可行性，以提供即时定量信息，支持治疗相关纳米颗粒的输送和循环。Tech将独立开发一种临床原型，放置在手指或其他光学可达位置，以监测输送剂量的准确性，并在静脉输送后立即评估有效循环时间，但在治疗干预之前。将评估原型提供三个临床目标的可行性：（1）为从业者提供真实的实时反馈，以提供瞬时初始剂量验证，（2）提供治疗剂量验证的实时反馈（np*min/mL），其是整合递送剂量和循环时间的药代动力学分析，以及（3）识别非特征性缩短的循环时间的报警系统，这可以帮助预测对纳米颗粒的生理反应，并且可能需要医疗干预。该项目的社会目标是“加速纳米技术的工作，…将纳米技术与癌症应用联系起来使用能够绕过生物屏障的多功能靶向设备，将高浓度的多种治疗剂直接输送到癌细胞和组织，同时保护健康组织，从而显着减少癌症的不良影响。这项拨款还旨在通过开发易于使用的成本意识仪器来解决癌症健康差异的问题，这些仪器专门用于解决“许多因素的影响，包括医生经验，医院环境和每个患者社区的社会人口统计学”。公共卫生相关性：纳米颗粒具有新的和改进的治疗和成像应用的重要前景，并正在被广泛研究。临床前和临床使用受到这些材料在体内的“生物利用度”的影响。这项研究计划将开发一种新的设备，用于实时跟踪这些新材料的循环动力学。